For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

UNITED THERAPEUTICS RECEIVES PRELIMINARY NOTICE OF APPROVAL FOR REMODULIN® IN SWITZERLAND AND AUSTRALIA

Research Triangle Park, NC and Silver Spring, MD, December 17, 2003: United Therapeutics Corporation (NSADAQ: UTHR) announced today that Switzerland's drug regulatory agency, SwissMedic, has issued a preliminary notice of approval for Remodulin (treprostinil sodium) Injection for the long-term treatment of primary pulmonary hypertension and pulmonary arterial hypertension associated with connective tissue disease in patients with NYHA Class III and IV symptoms. In addition, United Therapeutics received notice from the Australian Drug Evaluation Committee of the Therapeutic Goods Administration that it has recommended approval of Remodulin for the treatment of pulmonary arterial hypertension in patients with NYHA Class III and IV symptoms to diminish symptoms associated with exercise.

SwissMedic issued its approval pending final labeling and a commitment to perform an interaction study with an anticoagulant commonly used in Switzerland. The Australian Drug Evaluation Committee issued its approval recommendation pending final labeling.

"We will work closely with these agencies to finalize approvals which we expert in early 2004," said Dean Bunce, United Therapeutics' Vice President Regulatory Affairs.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

In addition to historical information, this press release contains forward-looking statements about expectations regarding marketing approval of Remodulin in Switzerland and Australia which are based on United Therapeutics' beliefs and expectations as to future outcomes. These expectations are subject to risks and uncertainties such as those described in United Therapeutics' periodic reports filed with the Securities and Exchange Commission which may cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics' periodic reports and documents filed with the Securities and Exchange Commission, including the company's most recent Form 10-K and Form 10-Q. United Therapeutics is providing this information as of December 17, 2003 and undertakes no obligation to publicly update or revise the information contained in this press release whether as a result of new information, future events or any other reason.